Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Pharma
Gilead races toward filings for long-acting PrEP after trial win
In a phase 3 study, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.
Zoey Becker
Sep 12, 2024 11:45am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
The TROP2 race for supremacy
Aug 16, 2024 9:45am
FDA approves Gilead's Livdelzi for primary biliary cholangitis
Aug 14, 2024 3:29pm
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
Merck, AstraZeneca, Gilead: The race for supremacy in an ADC field
Aug 2, 2024 4:00pm
